Neurovive Pharmaceutical: NeuroVive Share Upgraded on OTC Market in US
Business Wire - Fri Jun 26, 10:28AM CDT
Regulatory News:
Neurovive Pharmaceutical: Neurovive Reports Topline Results of Phase III CIRCUS Study in Acute Myocardial Infarction
Business Wire - Mon Jun 01, 1:47AM CDT
Regulatory News:
NeuroVive Asia Signs Collaboration Agreement with Sanofi for the Development and Commercialization of Ciclomulsion(R) in South Korea
Business Wire - Tue May 26, 3:30AM CDT
Regulatory News:
Neurovive Pharmaceutical: Topline Result of Phase III Study of Ciclomulsion(R) in Acute Myocardial Infarction Expected This Quarter
Business Wire - Mon May 25, 1:43AM CDT
Regulatory News:
Neurovive Pharmaceutical: NeuroVive: Interim report 1 Jan. 2015 till 31 Mar. 2015
Business Wire - Wed May 20, 1:54AM CDT
Regulatory News:
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 388.23 (-11.06), ACOR: 34.07 (+0.65), GSK: 42.45 (+0.65), AZN: 66.45 (+1.90), ATHX: 1.14 (-0.01), CUR: 1.69 (-0.01)
NeuroVive Pharmaceutical: NeuroVive Completes Share Issue Raising SEK 70 Million for the Preparation of CicloMulsion(R)'s Clinical Trial in the US and Commercialization in Europe
Business Wire - Fri May 08, 1:33AM CDT
Regulatory News:
NeuroVive Announces the Intention to Raise Additional Capital Through a Private Placement
Business Wire - Thu May 07, 10:50AM CDT
Regulatory News:
Neurovive Pharmaceutical: FIrst Patient Enrolled in Clinical Phase II Study for Kidney Protection During Heart Surgery
Business Wire - Mon Apr 27, 1:47AM CDT
Regulatory News:
Neurovive Pharmaceutical: Clinical Phase II Study with NeuroSTAT(R) for Traumatic Brain Injury Passes Safety Evaluation
Business Wire - Tue Apr 21, 3:06AM CDT
Regulatory News:
Neurovive Pharmaceutical: NeuroVive establishes subsidiary in Lyon and extends collaboration with HCL
Business Wire - Mon Apr 20, 1:41AM CDT
Regulatory News:
NeuroVive Pharmaceutical: Development of NVP014 for the Treatment of Stroke Enters New Phase in Collaboration with Isomerase Therapeutics
Business Wire - Fri Apr 17, 1:40AM CDT
Regulatory News:
NeuroVive Pharmaceutical reports change in number of shares and votes
M2 - Wed Apr 01, 3:08AM CDT
NeuroVive Pharmaceutical AB (STO:NVP), the mitochondrial medicine company, announced on Tuesday that the number of shares and votes of the company, registered with the Swedish Companies Registration Office, has increased by 1,300,000.
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
ChinaBio Today - at Seeking Alpha - Sun Feb 15, 10:14AM CST
Deals and Financings Cellular Biomedicine Group (NASDAQ: CBMG ), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story ). The two groups will...
NVO: 57.68 (+2.91), MRK: 57.95 (+0.57), QGEN: 25.73 (+1.00), CBMG: 29.80 (+0.31)
OnCore Biopharma and Tekmira Pharmaceuticals Files for Merger - Releases Further Details about License Agreement With NeuroVive
Business Wire - Thu Feb 05, 2:28AM CST
Regulatory News:
TKMR: 11.71 (+0.46)
Neurovive Pharmaceutical: NeuroVive and Skane University Hospital Initiate Collaboration on Clinical Phase II Study on Kidney Protection During Heart Surgery
Business Wire - Tue Dec 02, 1:40AM CST
Regulatory News:
NeuroVive reduces loss in third quarter 2014
M2 - Thu Nov 20, 4:57AM CST
NeuroVive Pharmaceutical AB (STO:NVP) on Wednesday reported loss before tax of SEK3,761,000, or diluted loss per share of SEK0.18, for the third quarter of 2014, from 1 July 2014 to 30 September 2014.